fcrn modulation as a targeted approach to myasthenia gravis management
Published 10 months ago • 256 plays • Length 1:04:32Download video MP4
Download video MP3
Similar videos
-
57:03
fcrn modulation in myasthenia gravis: applying the evidence, tools, and patient perspectives
-
1:07:10
generalized myasthenia gravis: targeted novel therapies to improve patient outcomes
-
18:58
what’s new for myasthenia gravis treatment: fcr inhibitor therapy
-
2:00
fcrn and the long half-life of igg antibodies
-
1:03
what is an fcrn blocker and how does it work?
-
1:16
about the fcrn
-
0:42
fda approves rsv antibody for infants
-
39:01
neonatal fc receptor in igg-mediated autoimmune disorders: looking at a common denominator
-
1:07
signaling pathways activated in mpns: targeting the dusp6-rsk1 pathway
-
1:52
fda revises authorization for 2 monoclonal antibody treatments
-
21:11
hesi am2016: hesi developmental and reprotox committee – fcrn tissue histology (graeme moffat)
-
1:50
fcrn model platform
-
1:18
what is fcrn and what does it do?
-
1:40
sf3b1 as therapeutic target in flt3/itd positive aml
-
3:08
rationale for targeting kit in asm
-
1:09
emerging treatment options for refractory immune thrombocytopenia
-
10:08
the pre-qualification process and medicines for children
-
1:21
optimal diagnostic pathway in mesothelioma
-
1:45
evaluating ipss-r and ipss-m in patients with hr-mds enrolled in stimulus-mds1 and stimulus-mds2